Range of diagnostic spinal fluid tests needed to differentiate concurrent brain diseases

April 20, 2012

Teasing out the exact type or types of dementia someone suffers from is no easy task; neurodegenerative brain diseases share common pathology and often co-occur. Researchers from the Perelman School of Medicine at the University of Pennsylvania are continuing efforts to differentiate diseases, such as Alzheimer's disease (AD) from frontotemporal lobar degeneration (FTLD), as FTLD is often clinically difficult to distinguish from atypical presentations of AD.

In a series of studies being presented at the American Academy of Neurology's 64th Annual Meeting in New Orleans, Penn researchers demonstrated that, while tests created for AD are effectively diagnosing the condition when it's clear cut, additional tests are needed to address the many cases with mixed pathology.

"With the emergence of disease-modifying treatments for AD and other , it will be of utmost importance to accurately identify the underlying in patients," said senior author John Q. Trojanowski, MD, PhD, professor of Pathology and Laboratory Medicine and co-director of the Center for Neurodegenerative Disease Research at Penn.

In one study, the Penn team compared results of a test looking at levels of tau and (Aβ) in the , using two different types of analytical platforms. They determined that values from the two platforms could effectively be transformed into equivalent units, and these values accurately distinguished AD from FTLD. A cutoff of 0.34 for the t-tau:Aβ1-42 ratio had 90 - 100 percent sensitivity and 91-96.7 percent specificity to differentiate FTLD cases, respectively.

In another study, the team looked at patient cases with more than one underlying neurodegenerative disease and compared the accuracy of the biomarkers using clinical and neuropathological diagnosis. They determined that cerebral spinal fluid (CSF) Aβ and tau assays provided a valid diagnosis of AD but, in mixed pathology cases where Alzheimer's was present along with other diseases (confirmed by autopsy), the testing strategies classified the diagnosis as AD alone.

"We need to develop better CSF diagnostic panels for the early diagnosis of neurodegenerative dementias, including those due to mixed neurodegenerative disease pathologies that commonly co-occur with Alzheimer's," said senior author Murray Grossman, MD, professor of Neurology and director of the Penn FTLD Center.

Explore further: Is it Alzheimer's disease or another dementia? Marker may give more accurate diagnosis

Related Stories

Is it Alzheimer's disease or another dementia? Marker may give more accurate diagnosis

November 30, 2011
New research finds a marker used to detect plaque in the brain may help doctors make a more accurate diagnosis between two common types of dementia – Alzheimer's disease and frontotemporal lobar degeneration (FTLD). ...

Changes seen in cerebrospinal fluid levels before onset of Alzheimer dementia

January 2, 2012
Cerebrospinal fluid levels of Aβ42 appear to be decreased at least five to 10 years before some patients with mild cognitive impairment develop Alzheimer disease (AD) dementia whereas other spinal fluid levels seem to ...

Study examines immunotherapy and cerebrospinal fluid biomarkers in patients with Alzheimer's disease

April 2, 2012
Immunotherapy with the antibody bapineuzumab in patients with mild to moderate Alzheimer disease resulted in decreases in a cerebrospinal fluid biomarker, which may indicate downstream effects on the degenerative process, ...

Study shows increased Alzheimer's biomarkers in patients after anesthesia and surgery

October 4, 2011
(Medical Xpress) -- The possibility that anesthesia and surgery produces lasting cognitive losses has gained attention over past decades, but direct evidence has remained ambiguous and controversial. Now, researchers at the ...

New hope for treating Alzheimer's Disease: A role for the FKBP52 protein

March 20, 2012
New research in humans published today reveals that the so-called FKBP52 protein may prevent the Tau protein from turning pathogenic. This may prove significant for the development of new Alzheimer's drugs and for detecting ...

Recommended for you

Alzheimer's Tau protein forms toxic complexes with cell membranes

November 22, 2017
The brains of patients with Alzheimer's disease contain characteristic tangles inside neurons. These tangles are formed when a protein called Tau aggregates into twisted fibrils. As a result, the neurons' transport systems ...

Researchers reveal new details on aged brain, Alzheimer's and dementia

November 21, 2017
In a comprehensive analysis of samples from 107 aged human brains, researchers at the Allen Institute for Brain Science, UW Medicine and Kaiser Permanente Washington Health Research Institute have discovered details that ...

Dementia study sheds light on how damage spreads through brain

November 20, 2017
Insights into how a key chemical disrupts brain cells in a common type of dementia have been revealed by scientists.

Researchers describe new biology of Alzheimer's disease

November 20, 2017
In a new study, researchers from Boston University School of Medicine (BUSM) describe a unique model for the biology of Alzheimer's disease (AD) which may lead to an entirely novel approach for treating the disease. The findings ...

Study shows video games could cut dementia risk in seniors

November 16, 2017
Could playing video games help keep the brain agile as we age?

New player in Alzheimer's disease pathogenesis identified

November 14, 2017
Scientists at Sanford Burnham Prebys Medical Discovery Institute (SBP) have shown that a protein called membralin is critical for keeping Alzheimer's disease pathology in check. The study, published in Nature Communications, ...

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.